- +91 8471002000
- Messenger
Immunotherapy
Pembrolizumab
Pembrolizumab Injection
Injection
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Pembrolizumab Dosage: IV infusion of 200mg every 3 weeks
Pembrolizumab, a groundbreaking medication, is sanctioned for addressing multiple malignancies, including melanoma, the non-small cell variant of lung cancer, squamous cell carcinoma in the head and neck regions, traditional Hodgkin's lymphoma, urothelial carcinoma, and stomach and esophagus cancer. Furthermore, it shows efficacy for neoplasms exhibiting microsatellite instability or dysfunctional mismatch repair. Pembrolizumab works by bolstering the body's immune response, enabling it to robustly target and eradicate tumor growth.
Pembrolizumab exemplifies an innovative immunotherapy tactic that invigorates the immune system of patients to detect and vanquish cancerous cells. Ingeniously impeding the functionality of the PD-1 protein, which enables cancer's immunity escape, this approach amplifies immune resilience. Pembrolizumab's remarkable versatility serves as an adept assailant against a spectrum of cancers, heralding a pioneering era in personalized oncology care strategies.
Pembrolizumab resistance arises from modifications in tumor cell composition, obstructing the inhibition of immune checkpoints and reducing T-cell interaction. As a result, cancer antigen presentation diminishes, while inhibitory elements increase, ultimately undermining pembrolizumab's efficacy and impairing its capacity to counteract cancer growth effectively.
Utilizing Pembrolizumab injection may result in various undesired reactions, encompassing perpetual fatigue, relentless coughing, sensations of queasiness, and aggravated skin conditions. In distinct situations, this therapeutic agent can provoke grave consequences like self-destructive organ assaults, lung-related swellings, hepatic issues, or severe infusion-linked complications. Ongoing supervision is essential for quick detection and management of these potential risks.
Pembrolizumab, a potent cancer therapy agent, can be effectively employed alongside various drugs, depending on the specific cancer. For non-squamous non-small cell lung cancer (NSCLC), a combination of pembrolizumab, pemetrexed, and platinum-based chemotherapies such as cisplatin or carboplatin is commonly utilized. Furthermore, the FDA has authorized the concurrent use of pembrolizumab and axitinib to address advanced renal cell carcinoma (RCC). Seeking expert medical advice is essential to determine an optimal treatment plan.
Avg. Pembrolizumab Injection cost: ₹64,000 in India. The above price is specific for Rayagada, Odisha, India
WhatsApp us